Anti-CD38 Antibody-Drug Conjugate (ADC) STI-6129 For Amyloid Degeneration: FDA Approved FORIND
-
Last Update: 2020-05-30
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Sorrento Pharmaceuticals Incannounced today that the U.SFDA has approved a new application for a new drug (IND) for STI-6129 to treat amyloid degenerationSTI-6129 incorporates a variety of technologies: whole-human-source anti-CD38-specific anti-CD38-specific antibody and site-specific C-LOCK coupling techniques identified from the G-MAB ™ Antibody LibraryDr Henry Ji, Chairman and CEO of Sorren Therapeutics, said, "StI-6129, together with our CD38 CAR-T program, is expected to be a treatment option for patients with amyloid degenerationWe look forward to further evaluating the safety and effectiveness of STI-6129 in clinical trials." Sorrento intends to initiate Phase I multicenter, open label, dose-increasing clinical trials in patients with late-stage relapse and/or refractory systemic amyloid albinism, primarily to determine the safety, initial efficacy, and pharmacokinetic characteristics of STI-6129amyloidosis is a generic term used to refer to the deposition of primary fibers consisting of low molecular weight subunits of various proteins, most of which circulate as plasma componentsThese deposits can lead to many different clinical manifestations, depending on the type of sediment, sedimentation site and amount of sediment
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
